OMER:NASDAQ

Omeros Corp.

Omeros Corp. is a clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Lead drug product Omidria (OMS302) for lens replacement surgery is under review for marketing approval by both FDA and the European Medicines Agency, with U.S. commercial launch planned for H2/14. Omeros' five other clinical programs are focused on schizophrenia; Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros' proprietary G protein-coupled receptor (GPCR) platform is making available many new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Expert Comments:

Jason Kolbert, Maxim Group (3/17/15)
"Omeros Corp. ended 2014 with $6.8M in cash. . .for Omidria, the company began a 'controlled launch' in February to test its marketing and distribution systems. The full launch is planned for April, when the American Society of Cataract and Refractive Surgery holds its annual meeting. . .in addition to the PharmacoSurgery platform, Omeros has a pipeline of other products with high potential."

Ram Selvaraju, MLV & Co (3/13/15)
"We remain confident that Omeros Corp. is close to officially launching Omidria and project sales revenue starting in Q2/15. The transitional pass-through Medicare reimbursement status for Omidria is favorable. . .we believe that the European Medicines Agency will approve Omidria for the same indication in the E.U. in mid-2015. . .we continue to project that Omeros could achieve cash-flow-positive status in late 2015, and reach sustainable profitability in 2018 driven by the revenue trajectory for Omidria. . .we project that development of OMS824 for Huntington's disease (HD) will continue in H1/15. . .clinical trials in HD patients by H2/15."

Zacks Equity Research (3/3/15)
"One company that looks well positioned for a solid gain but has been overlooked by investors lately is Omeros Corp. . .this year's expected earnings growth over the prior year is 45.5%, which should ultimately translate into price appreciation. . .now might be an interesting buying opportunity." -Zacks Equity Research

Jason Kolbert, Maxim Group (3/2/15)
"In January 2015, Omeros Corp. raised about $84M in a public offering. This should provide enough cash to launch Omidria (OMS302) and fund its development pipeline. . .we expect Omidria to be launched soon."

Jason Kolbert, Maxim Group (2/20/15)
"Omeros Corp. announced results from the first cohort in the phase 2 trial of OMS721, its complement inhibitor, in atypical hemolytic uremic syndrome. All three patients treated with the lowest dose planned showed meaningful improvements in measures of disease, justifying treating a second cohort with a mid-level dose of OMS721. . .we see this as a success for OMS721. . .we are raising our price target to $30/share from $28/share."

George Zavoico, MLV & Co (2/18/15)
"We are raising our one year price target for Omeros Corp. from $19/share to $38/share after a thorough analysis of the company's outlook for 2015 and beyond. We increased our previous U.S. market projections for Omidria after Omeros doubled its sales force to 40 sales representatives, and foresee several potential catalysts for Omeros in 2015. . .with its comfortable cash position, we think Omeros is in a much better position to negotiate partnerships for Omidria's ex-U.S. markets or for other assets, and is well-prepared for Omidria's imminent market launch in the U.S."

More Comments

Experts Commenting on This Company


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.